Neogen Corp (NEOG): Shareholders' Equity

Annual figures by period end, from SEC filings.

$2.09B
As of 2026-05-31
-12.6%
3-year compound annual growth
+20.0%
5-year compound annual growth
+17.9%
10-year compound annual growth
$3.14B2010-05-31: $153.05M2011-05-31: $189.10M2012-05-31: $219.05M2013-05-31: $258.29M2014-05-31: $306.30M2015-05-31: $350.96M2016-05-31: $404.16M2017-05-31: $471.76M2018-05-31: $560.17M2019-05-31: $637.90M2020-05-31: $725.18M2021-05-31: $840.38M2022-05-31: $887.37M2023-05-31: $3.13B2024-05-31: $3.14B2025-05-31: $2.07B2026-05-31: $2.09B$2.09B
2010-05-31 Shareholders' Equity (USD) 2026-05-31
Period endedShareholders' EquityChange YoYSource filing
2026-05-31$2.09B+1.0%2026-07-30, Balance as of period end
2025-05-31$2.07B-34.1%2026-07-30, Balance as of period end
2024-05-31$3.14B+0.3%2026-07-30, Balance as of period end
2023-05-31$3.13B+253.2%2025-07-30, Balance as of period end
2022-05-31$887.37M+5.6%2024-07-30, Balance as of period end
2021-05-31$840.38M+15.9%2023-08-15, Balance as of period end
2020-05-31$725.18M+13.7%2022-07-27, Balance as of period end
2019-05-31$637.90M+13.9%2021-07-30, Balance as of period end
2018-05-31$560.17M+18.7%2020-07-30, Balance as of period end
2017-05-31$471.76M+16.7%2019-07-30, Balance as of period end
2016-05-31$404.16M+15.2%2018-07-27, Balance as of period end
2015-05-31$350.96M+14.6%2017-07-28, Balance as of period end
2014-05-31$306.30M+18.6%2016-07-29, Balance as of period end
2013-05-31$258.29M+17.9%2015-07-30, Balance as of period end
2012-05-31$219.05M+15.8%2014-07-30, Balance as of period end
2011-05-31$189.10M+23.6%2013-07-30, Balance as of period end
2010-05-31$153.05Mn/a2012-07-30, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Neogen Corp (NEOG)2026-05-31$2.09B+1.0%
Myriad Genetics Inc (MYGN)2025-12-31$368.00M-47.5%
Lantheus Holdings, Inc. (LNTH)2025-12-31$1.09B+0.2%
QuidelOrtho Corp (QDEL)2025-12-28$1.92B-35.7%
Idexx Laboratories Inc (IDXX)2025-12-31$1.61B+0.6%
Intellia Therapeutics, Inc. (NTLA)2025-12-31$671.39M-23.0%
Alpha Teknova, Inc. (TKNO)2025-12-31$68.78M-16.5%
Immucell Corp (ICCC)2025-12-31$27.06M-1.7%
Aspira Women's Health Inc. (AWHL)2025-12-31-$6.93Mn/m

Compare NEOG, MYGN, LNTH, QDEL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗